CytoDyn (CYDY) Intangibles (2012 - 2022)
CytoDyn's (CYDY) quarterly Intangibles came in at $132000.0 in Q2 2022, down 92.01% YoY from $1.7 million in Q2 2021, and down 87.34% on a QoQ basis from $1.0 million in Q1 2022.
CytoDyn (CYDY) Intangibles (2012 - 2022) Analysis & Trends
CytoDyn (CYDY) has 11 years of Intangibles data on file, last reported at $132000.0 in Q2 2022.
- Quarterly Intangibles fell 92.01% year-over-year to $132000.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was $132000.0 (down 92.01% YoY) and the FY2022 annual result came in at $132000.0, down 92.01% from the prior year.
- Intangibles slipped to $132000.0 in Q2 2022, from $1.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $16.5 million in Q4 2018 to a low of $35989.0 in Q1 2018.
- A 5-year average of $6.7 million and a median of $2.7 million in 2019 frame the typical range for Intangibles.
- The widest YoY moves for Intangibles: up 45616.61% in 2018, down 98.17% in 2018.
- Tracing CYDY's Intangibles over 5 years: stood at $16.5 million in 2018, then dropped by 12.17% to $14.5 million in 2019, then declined by 13.76% to $12.5 million in 2020, then slumped by 90.75% to $1.2 million in 2021, then tumbled by 88.55% to $132000.0 in 2022.
- The last three Intangibles figures came in at $132000.0 (Q2 2022), $1.0 million (Q1 2022), and $1.2 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 132,000.00 |
| Feb 28, 2022 | 1.04 Mn |
| Nov 30, 2021 | 1.15 Mn |
| Aug 31, 2021 | 1.39 Mn |
| May 31, 2021 | 1.65 Mn |
| Feb 28, 2021 | 1.92 Mn |
| Nov 30, 2020 | 12.46 Mn |
| Aug 31, 2020 | 12.96 Mn |
| May 31, 2020 | 4.60 Mn |
| Feb 29, 2020 | 13.95 Mn |
| Nov 30, 2019 | 14.45 Mn |
| Aug 31, 2019 | 3.50 Mn |
| May 31, 2019 | 15.48 Mn |
| Feb 28, 2019 | 15.95 Mn |
| Nov 30, 2018 | 16.45 Mn |
| Aug 31, 2018 | 1.44 Mn |
| May 31, 2018 | 1.57 Mn |
| Feb 28, 2018 | 35,989.00 |
| Nov 30, 2017 | 35,989.00 |
| Aug 31, 2017 | 1.83 Mn |